DSUTMA (Does Science Use Too Many Abbreviations)?

Jumble of letters
Photo by Nathaniel Shuman / Unsplash

Science has a reputation for being very complicated, sometimes to its own detriment. One way that this manifests is the use of acronyms, initialisms, and other abbreviations, theoretically designed to make life easier for the reader but often, in my experience, leading to some confusion when read out of context.

To test this theory, I conducted the extremely scientific experiment of going to the open-access journal BMJ Open, and clicking on an article on the front page from the “Most Read Article” list (the category in this case was “Pharmacology and Therapeutics”). I then scrolled to the discussion section, where the first sentence reads as follows:

“This report described the protocol for a 16-week, phase II RCT to investigate the efficacy of LDN for treating fatigue severity in patients with PCFS, an illness we have defined as ME/CFS symptoms persisting at least 3 months following SARS-CoV-2 infection.” - Naik et. al

As you can see, there are indeed a large number of abbreviations in this example. But how prevalent is this, and is it a problem?

How often do papers use abbreviations?

A paper published in 2020 sought to see how widely used acronyms were in scientific papers. Researchers analyzed around 24 million articles, published from the 1950s to the 2010s. They found over 1 million unique acronyms had been used, but of those, only 0.2% (just over 2000) were used regularly, and about 4 in 5 acronyms were used less than 10 times ever. Around 20% of titles included an acronym, and around 75% of abstracts. They also found that the prevalence increased over time, from 0.7 per 100 words in 1950 to 2.4 per 100 by 2019.

Chart showing acronym usage in papers
Trust me, there is a line for more than 10,000 (it's just small)

What’s clear, then, is that acronyms are not only very prevalent within science publications, they are increasingly prevalent. It is also clear that the vast majority of acronyms are acronyms that are hardly ever used.

The researchers also compiled a list of the most commonly used acronyms:

Rank

Acronym

Common meaning(s)

Count

1

DNA

Deoxyribonucleic acid

2,443,760

2

CI

Confidence interval

1,807,878

3

IL

Interleukin/Independent living

1,418,402

4

HIV

Human immunodeficiency virus

1,172,516

5

mRNA

Messenger ribonucleic acid

1,107,547

6

RNA

Ribonucleic acid

1,060,355

7

OR

Odds ratio/Operating room

788,522

8

PCR

Polymerase chain reaction

745,522

9

CT

Computed tomography

743,794

10

ATP

Adenosine triphosphate

582,838

11

MS

Multiple sclerosis/Mass spectrometry

567,523

12

MRI

Magnetic resonance imaging

504,823

13

TNF

Tumour necrosis factor

454,486

14

US

United States/Ultrasound/Urinary system

436,328

15

SD

Standard deviation

411,997

16

NO

Nitric oxide

394,777

17

PD

Parkinson's disease/Peritoneal dialysis

389,566

18

HR

Heart rate/Hazard ratio

383,027

19

IFN

Interferon

383,011

20

CD4

Cluster of differentiation antigen 4

363,502

Looking at this list, we can see that DNA is (by far) the most used acronym, which makes sense, and is one that’s hard to complain about as its more or less universally understood. Others, like CD4 (Cluster of differentiation antigen 4) are ones that laypeople such as myself have never heard of, but I assume are relatively well-known within their fields. 6 of the 20, however, appear to be acronyms that can mean multiple things, including things that could definitely be in the same paper (e.g. United States/Ultrasound/Urinary system).

So is this a problem?

There have been calls from several people about reducing the use of abbreviations iin science, including a suggestion to reduce the use to three acronyms, and a recommendation by the American Chemical Society to avoid abbreviations in the titles of papers (ironically, they wrote this in the “ACS Style Guide”).

In defence of abbreviations, there are many good reasons why scientists use them. One is that in many cases, the names of things are long and/or complicated, and using acronyms can help cut down on that, allow writing to flow easier and (particularly in the case of things like grants) reduce the length of writing. Another is that in many fields, abbreviations are part of the common language of researchers, and therefore are both widely-used among peers and also widely-understood. Considering the fact that the audience of scientific publications is usually other scientists, it makes sense to use language common with this audience. When you read a paper, they will always explain what an abbreviation means the first time they use it, to avoid confusion. Acronyms are also sometimes used by researchers (and politicians) to coin a catchy name for something, like the Consolidated Standards of Reporting Trials (CONSORT) diagram, which otherwise might be more forgettable.

purple and black letters
Photo by BP Miller / Unsplash

On the other hand, there are many issues with the use of abbreviations. The obvious one is that many times, it just isn’t that clear what they mean. It’s common to skim a paper rather than read it fully, and so that can become a lot more difficult when abbreviations are used throughout the paper. Even when you’re reading a paper fully, it’s not unusual to reach a table that contains 10 different abbreviations, none of which are obvious, and then have to flip back and check what each one means. Sometimes authors assume an abbreviation is well-known, so they don’t clarify what it means, which can lead to additional confusion. A study found that a full 22% of abstracts used language so complicated that they cannot be considered readable by someone with college-level English.

The use of abbreviations as jargon can also harm interdisciplinarity. By relying on language and ways of communicating developed in specific fields, abbreviations can make it seem more daunting for people from different disciplines to understand papers. While a researcher can of course check to see what the acronyms and initialisms all mean, it is inevitable that they will feel alienated when they see abbreviations that they don’t recognize being used again and again. One study found, unsurprisingly, that using more jargon in your title and abstract significantly reduces the chances of being cited.

There are also certain abbreviations that need to be considered more in-depth before they are used. Consider the examples mentioned above of acronyms that mean different things in different contexts. Another example is the use of AAPI (Asian American and Pacific Islander), which has been noted in the past by groups such as the Asian American Journalists Association as one that can be controversial, as it groups together communities that sometimes might want to be differentiated. Researchers might default to using acronyms like these without really thinking about what the implications of using them might be.

So what to do?

Overall, there are bigger issues with science communication than the use of abbreviations. But abbreviations are definitely part of a larger trend of insularity within science publications that reduces the amount that articles can be understood and limits the impact they can make outside the scientific community. For all of their benefits, the current state of abbreviations in science leaves a lot to be desired, and is probably doing more harm than good. While abbreviations still have their place, there should be more consideration by authors of the ways in which they are using them. Abbreviations that are understood by many, and acronyms that are used to aid memorability, are examples of abbreviations that can be very helpful. Other abbreviations, like ones that will never be used again, ones that can be confused with other abbreviations, or ones that can alienate or dehumanize groups, should be avoided if possible. While it is obviously a subjective process, researchers taking more time to consider when and how to use abbreviations will lead to greater interdisciplinarity, comprehensibility, and impact for their work.

Sources

Main source:

Meta-Research: The growth of acronyms in the scientific literature
A study of 24 million articles has revealed that scientists have created more than 1 million acronyms since 1950, most of which have been used fewer than 10 times.

Other:

Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia
Introduction A significant proportion of individuals suffering from post COVID-19 condition (PCC, also known as long COVID) can present with persistent, disabling fatigue similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-viral fatigue syndromes. There remains no clear pharmacological therapy for patients with this subtype of PCC, which can be referred to as post-COVID fatigue syndrome (PCFS). A low dose of the opioid antagonist naltrexone (ie, low-dose naltrexone (LDN)) has emerged as an off-label treatment for treating fatigue and other symptoms in PCC. However, only small, non-controlled studies have assessed LDN in PCC, so randomised trials are urgently required. Methods and analysis A prospective, randomised, double-blind, parallel arm, placebo-controlled phase II trial will be performed to assess the efficacy of LDN for improving fatigue in PCFS. The trial will be decentralised and open to eligible individuals throughout the Canadian province of British Columbia (BC). Participants will be recruited through the province-wide Post-COVID-19 Interdisciplinary Clinical Care Network (PC-ICCN) and research volunteer platform (REACH BC). Eligible participants will be 19–69 years old, have had a confirmed or physician-suspected SARS-CoV-2 infection at least 3 months prior and meet clinical criteria for PCFS adapted from the Institute of Medicine ME/CFS criteria. Individuals who are taking opioid medications, have a history of ME/CFS prior to COVID-19 or history of significant liver disease will be excluded. Participants will be randomised to an LDN intervention arm (n=80) or placebo arm (n=80). Participants in each arm will be prescribed identical capsules starting at 1 mg daily and follow a prespecified schedule for up-titration to 4.5 mg daily or the maximum tolerated dose. The trial will be conducted over 16 weeks, with assessments at baseline, 6, 12 and 16 weeks. The primary outcome will be fatigue severity at 16 weeks evaluated by the Fatigue Severity Scale. Secondary outcomes will include pain Visual Analogue Scale score, overall symptom severity as measured by the Patient Phenotyping Questionnaire Short Form, 7-day step count and health-related quality of life measured by the EuroQol 5-Dimension questionnaire. Ethics and dissemination The trial has been authorised by Health Canada and approved by The University of British Columbia/Children’s and Women’s Health Centre of British Columbia Research Ethics Board. On completion, findings will be disseminated to patients, caregivers and clinicians through engagement activities within existing PCC and ME/CFS networks. Results will be published in academic journals and presented at conferences. Trial registration number [NCT05430152][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT05430152&atom=%2Fbmjopen%2F14%2F5%2Fe085272.atom
First Impressions of Your Science: Title Matters - PubMed
First Impressions of Your Science: Title Matters
CONSORT: when and how to use it - PMC
Research: The readability of scientific texts is decreasing over time
Scientific abstracts have become less readable over the past 130 years, in part because recent texts include more general scientific jargon than older texts.

https://royalsocietypublishing.org/doi/10.1098/rspb.2020.2581

AAJA Pacific Islander Task Force Urges Mindful Reporting in Coverage of Indigenous Pacific Islanders - Asian American Journalists Association
As coverage of the Tokyo Olympics continues, The Asian American Journalists Association’s (AAJA) Pacific Islander Task Force urges media organizations to be mindful in their reporting not to perpetuate stereotypes about Indigenous Pacific Islanders in headlines and coverage.